Atossa Therapeutics Inc Stock Price, News & Analysis

Atossa Therapeutics (Nasdaq: ATOS) reported its financial results for the year ended December 31, 2022, highlighting significant clinical advancements. The company initiated its Phase 2 EVANGELINE study for neoadjuvant treatment in premenopausal women with ER+ breast cancer and continues enrollment in the Karisma-Endoxifen study. Notably, Atossa added a new arm to the ongoing I-SPY 2 trial, evaluating (Z)-endoxifen. Financially, the company reported an operating loss of $27.7 million, a 35% increase from 2021, driven mostly by rising R&D costs. Cash reserves stood at approximately $111 million, supporting ongoing clinical endeavors.

Atossa Therapeutics (Nasdaq: ATOS) announces its proprietary Selective Estrogen Receptor Modulator, (Z)-endoxifen, will be assessed in a new arm of the I-SPY 2 clinical trial targeting locally advanced breast cancer. This trial, involving approximately 20 patients, aims to evaluate treatment effectiveness prior to surgery. The study focuses on estrogen receptor-positive invasive breast cancer patients, who have high recurrence risks and require more effective treatments. Dr. Steven Quay highlighted the urgency of new alternatives for these patients. Atossa is also conducting two Phase 2 studies for (Z)-endoxifen with promising implications for breast cancer management.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced its participation in the Sidoti Small-Cap Virtual Conference, scheduled for March 22-23, 2023. Dr. Steven Quay, the Company’s President and CEO, along with Kyle Guse, General Counsel and CFO, will present on March 23 at 1:00 PM Eastern Time. Investors can register for the live webcast through the event's website. A recording will also be made available post-conference on Atossa's investor relations page. Atossa focuses on developing innovative medicines for unmet medical needs in oncology, particularly breast cancer.

Atossa Therapeutics (Nasdaq: ATOS) has initiated the Phase 2 EVANGELINE study, dosing its first patient for a trial evaluating the efficacy of (Z)-endoxifen versus exemestane plus goserelin in treating ER+/HER2- breast cancer in premenopausal women. This randomized study aims to assess the endocrine sensitive disease rate after four weeks of treatment with approximately 175 participants across 25 sites in the U.S. The previous study showed (Z)-endoxifen reduced Ki-67 by 65.1%, indicating potential efficacy. Atossa is also exploring (Z)-endoxifen's application in reducing mammographic breast density, an important breast cancer risk factor.

Atossa Therapeutics (Nasdaq: ATOS) announced the granting of a new patent (No. 11,572,334) by the USPTO for (Z)-endoxifen encapsulated in an enteric capsule, enhancing its intellectual property related to this compound. This patent positions Atossa as the sole provider of orally delivered (Z)-endoxifen with an enteric capsule in the U.S., aimed at optimizing drug delivery. The company is advancing Phase 2 trials, including the EVANGELINE study with approximately 175 participants and the Karisma-Endoxifen study with 240 participants, targeting unmet needs in breast cancer treatment. The new patent is expected to create long-term value for shareholders.

Atossa Therapeutics (Nasdaq: ATOS) announced significant progress in 2022, focusing on its breast cancer program with the patented (Z)-endoxifen. Currently, Phase 2 studies are underway to prevent and treat breast cancer, particularly targeting ER+/HER2- patients. The FDA authorized the EVANGELINE study for neoadjuvant treatment, expecting to enroll 175 patients across 25 sites. The company reported a 65.1% reduction in Ki-67 levels from a prior study, suggesting improved outcomes. Atossa also invested $4.7 million in Dynamic Cell Therapies, enhancing its oncology portfolio. As of September 30, 2022, Atossa holds approximately $117 million in cash and equivalents, with no debt.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has appointed Eric Van Zanten as Vice President of Investor and Public Relations. With over 25 years in corporate communications, particularly in biopharmaceuticals, Van Zanten will enhance the company's investor and public messaging. His previous roles include leadership positions at Faron Pharmaceuticals and Bristol-Myers Squibb. CEO Steven Quay expressed confidence in Van Zanten's ability to articulate Atossa's mission in oncology. Atossa focuses on innovative cancer treatments, specifically targeting breast cancer and lung injury from therapies.